Abbott Laboratories (NYSE:ABT – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a report released on Friday,Benzinga reports. They currently have a $131.00 price objective on the healthcare product maker’s stock. BTIG Research’s price target would indicate a potential upside of 37.79% from the stock’s current price.
ABT has been the topic of a number of other research reports. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Daiwa Securities Group lowered their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Weiss Ratings downgraded Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, Stifel Nicolaus lowered their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $132.60.
View Our Latest Stock Report on ABT
Abbott Laboratories Price Performance
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.
Insider Activity at Abbott Laboratories
In other news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.
Institutional Investors Weigh In On Abbott Laboratories
A number of institutional investors have recently made changes to their positions in the company. CPC Advisors LLC boosted its holdings in shares of Abbott Laboratories by 36.9% during the first quarter. CPC Advisors LLC now owns 28,066 shares of the healthcare product maker’s stock worth $2,882,000 after acquiring an additional 7,567 shares during the period. Roble Belko & Company Inc boosted its holdings in shares of Abbott Laboratories by 27.5% during the first quarter. Roble Belko & Company Inc now owns 700 shares of the healthcare product maker’s stock worth $72,000 after acquiring an additional 151 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO boosted its holdings in shares of Abbott Laboratories by 25.5% during the first quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 58,941 shares of the healthcare product maker’s stock worth $6,051,000 after acquiring an additional 11,994 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Abbott Laboratories by 114.4% during the first quarter. SG Americas Securities LLC now owns 2,064,157 shares of the healthcare product maker’s stock worth $211,927,000 after acquiring an additional 1,101,364 shares during the period. Finally, Smith Salley Wealth Management boosted its stake in shares of Abbott Laboratories by 1.3% in the first quarter. Smith Salley Wealth Management now owns 189,613 shares of the healthcare product maker’s stock valued at $19,468,000 after buying an additional 2,448 shares during the period. Institutional investors own 75.18% of the company’s stock.
More Abbott Laboratories News
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Q1 results narrowly beat expectations: adjusted EPS $1.15 vs. $1.14 consensus and revenue $11.16B (up 7.8% y/y), supported by cancer-diagnostics and medical-device strength. Abbott first-quarter results beat on cancer diagnostics, medical device strength
- Positive Sentiment: Exact Sciences acquisition expands Abbott into high-growth oncology diagnostics and is presented as strategic long-term growth even though it creates near-term EPS dilution. Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
- Positive Sentiment: Broker support and insider activity: RBC Capital reaffirmed its buy rating and company insiders added shares, both signals of continued institutional/management confidence. RBC Capital Reaffirms Their Buy Rating on Abbott Laboratories (ABT) Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings
- Negative Sentiment: Guidance cut and dilution: Abbott lowered FY2026 adjusted EPS to $5.38–$5.58 (includes ~$0.20/share dilution from Exact Sciences) and Q2 EPS to $1.25–$1.31, below Street expectations — the guidance hit is the primary reason investors sold shares. Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings
- Negative Sentiment: Margin pressure and weak Nutrition segment: management flagged margin compression and a prolonged slump in nutrition sales (plus a milder flu season that hurt consumer-test volumes), which weigh on near-term profit recovery. Abbott Stock Falls Despite Q1 Earnings & Revenue Beat Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
- Negative Sentiment: Market reaction: Despite the beat, investors focused on the weaker guide and merger-related costs, sending the stock lower (coverage pieces and commentaries explain the selloff). Why Abbott Laboratories Stock Tumbled on Thursday
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Recommended Stories
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
